Jazz Pharmaceuticals
Jazz Pharmaceuticals commercialises zanidatamab (Ziihera) outside Asia.
Zanidatamab in biliary tract and gastro-oesophageal cancer; Rylaze, Zepzelca.
Zanidatamab (Ziihera) is an antibody that grabs HER2 at two different spots, approved for HER2+ bile duct cancer.
An enzyme that starves leukaemia cells of an amino acid they cannot make; a mainstay of childhood ALL therapy for 50 years, with new versions solving allergy and supply problems.
The two old chemotherapy drugs packed together into tiny fat bubbles at a fixed ratio, which doubled five-year survival in older adults with high-risk AML.
Dordaviprone is the first drug ever approved for a lethal childhood and young-adult brain tumour, diffuse midline glioma with the H3 K27M mutation (August 2025).
A marine-derived chemotherapy that jams cancer's gene-reading machinery, approved for relapsed small-cell lung cancer and, since 2025, as first-line maintenance with atezolizumab.
Pages like this
not linked directly; found by shared links- CompanyPharmaMar
Shares Lurbinectedin, Ewing sarcoma, Small-cell lung cancer.
- CompanyZymeworks
Shares Zanidatamab, Biliary tract cancer (cholangiocarcinoma), HER2-positive breast cancer.
- TrialCPX-351 Study 301
Shares CPX-351 (liposomal daunorubicin-cytarabine), Acute myeloid leukaemia.
- CompanyServier
Shares Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase), Biliary tract cancer (cholangiocarcinoma), Glioma & glioblastoma, Acute myeloid leukaemia.
- TrialATLANTIS
Shares Lurbinectedin, Small-cell lung cancer.
- TrialIMforte
Shares Lurbinectedin, Small-cell lung cancer.
- TrialHERIZON-GEA-01
Shares Zanidatamab, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer.
- TrialHERIZON-BTC-302
Shares Zanidatamab, Biliary tract cancer (cholangiocarcinoma).